Chinese innovative drug stocks surge at open; four hit limit up

The absence of any disclosed catalyst is itself the story here: a broad-based limit-up cluster across large-cap names like Hongbo and Zhongheng, plus double-digit gains in smaller listings, points to sector-wide positioning rather than company-specific news. That breadth matters because it suggests capital is rotating back into the innovative-drug theme as a group, not picking winners. The open question is whether this holds through the session or fades once the initial flow is absorbed, and whether any concrete policy or pipeline trigger emerges to justify the move.